Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Sciegen Pharmaceuticals Inc
EIR
•Sciegen Pharmaceuticals Inc•March 16, 2018

Sciegen Pharmaceuticals Inc – FDA EIR, Mar 16, 2018

Record Details

This FDA Establishment Inspection Report documents a post-approval inspection of Sciegen Pharmaceuticals Inc., a non-sterile generic prescription drug manufacturer located in Hauppauge, NY. The inspection occurred from March 12 to March 16, 2018. Its primary purpose was to assess post-approval compliance for Fluoxetine capsules and Hydrochlorothiazide tablets, and to verify the implementation of corrective actions from a previous FDA inspection conducted between December 29, 2014, and January 9, 2015. The earlier inspection had identified an issue with the quality control unit's adherence to procedures, specifically concerning an inadequate laboratory investigation into duplicate sample testing for Metformin Hydrochloride Tablets. The current inspection, performed under Compliance Program 7346.843 for post-approval audits, concluded without any new inspectional observations or findings (FDA-483) being issued. This indicates that the firm's operations for the inspected products and its response to previous issues were found to be satisfactory. The inspection was classified as "No Action Indicated," signifying compliance with regulatory standards in the areas reviewed.

Company
Sciegen Pharmaceuticals Inc
Inspection date
March 16, 2018
Product type
RX (Prescription)
Office
Food and Drug Administration
Person
  • Paul C. Mouris (GDUFA Supervisory Investigator)
View Company Profile

ID · 97b96d96-bcf3-4cd3-9989-1544618d657f

Other documents for Sciegen Pharmaceuticals Inc
  • 483 - 2023-04-17April 17, 2023
  • 483 - 2022-09-02September 2, 2022
  • 483 - 2021-12-20December 20, 2021
  • EIR - 2019-06-21June 21, 2019
  • 483 - 2015-01-09January 9, 2015

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Sciegen Pharmaceuticals Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.